Ефективність і доцільність використання нутрицевтиків з ресвератролом у пацієнтів з високою ускладненою міопією

Abstract

The paper is dedicated to the study of the efficiency of nutraceutical with resveratrol and vitamins and antioxidants of AREDS (Age-Related Eye Disease Studies) formula in patients with high myopia. Seventy-five patients (150 eyes) with high axial myopia (–7.0 to –20.0 diopters) and chorioretinal dystrophy were examined. Group I included 21 patients (42 eyes) who received conservative nootropic and metabolic therapy; group II included 34 patients (68 eyes) who received a nutraceutical containing 60 mg of trans-resveratrol combined with components of AREDS formula, omega-3 fatty acid and vitamin D (Resvega®Forte) at the end of nootropic and metabolic therapy; group III included 20 patients (40 eyes) who did not receive conservative treatment. The effectiveness of treatment was evaluated based on maximal corrected visual acuity (MCVA), phosphene threshold (PT) and the findings of optical coherence tomography of the macula (foveal thickness (FT) and subfoveal choroidal thickness (SCT)) every 6 months before and after treatment. In patients of group II, the MCVA increase during the first year was 29.8% versus baseline (p=0.005), and the achieved therapeutic effect was maintained until the end of the second year of the follow-up period. The patients of group III showed MCVA decrease by 19.1% after 24 months from the start of the follow-up period. Despite the absence of statistical difference in baseline MCVA in all the groups, MCVA in patients of group III was lower than that in patients of group II after 12 months and lower than that in patients of group I (p˂0.0002) after 24 months. There was a 4.7 % increase in FT in patients of group III versus baseline (p˂0.05). The patients of group III showed a 34.4% decrease in SCT versus baseline (p<0.05). Thus, the use of nutraceuticals with resveratrol and antioxidants of AREDS formula in the comprehensive treatment of patients with myopic chorioretinal dystrophies allows to achieve good functional results with stable foveal thickness without signs of myopic choroidal vascularization and preservation of subfoveal choroidal thickness.